Bendamustine HCl (TREANDATM) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).
Katherine Robinson(Queen Elizabeth II Health Sciences Centre), Ely Benaim, Robin Joyce(Beth Israel Deaconess Medical Center), Anil Tulpule(University of Southern California), Jordan A. Herst(Health Sciences North), Jennifer Oliver, Alberto Bessudo(California Cancer Associates for Research and Excellence), Michael E. Williams(University of Virginia), Bernard Lemieux(Centre Hospitalier Universitaire Sainte-Justine), Richard H. van der Jagt(Ottawa Hospital), Lee S. Schwartzberg(Renown Health), Philip Cohen(Georgetown University)
Cited by 9
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k